Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897186 | 0.89 | MAOA (0.59) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2932209 | 0.88 | MAOA (0.57) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6819289 | 0.88 | MAOA (0.56) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2933661 | 0.87 | MAOA (0.56) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5213883 | 0.87 | MAOA (0.68) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5883140 | 0.85 | MAOA (0.55) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL29446267 | 0.85 | TACR2 (0.62) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL584489 | 0.85 | TACR2 (0.62) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4003173 | 0.84 | DRD2 (0.54) | MAOAMAOBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL19251015 | 0.84 | MAOA (0.46) | MAOAMAOBALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | disclosed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-8785681-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2014-07-22 | — | — | US | disclosed |
| EP-2125711-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Albireo Ab (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | disclosed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | disclosed |
| WO-2008108735-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007147491-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-27 | — | — | WO | disclosed |
| CN-1206212-C | Tri-substd. phenyl derivs. and analogues | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | CN | disclosed |
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1402703-A | Tri-substd. phenyl derivs. and analogues | ASTRAZENECA AB (SE) | 2003-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | MAOA 200/4885MAOB 129/4885ALDH1A1 593/4885 |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | MAOA 2346/4885MAOB 1929/4885ALDH1A1 852/4885 |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | MAOA 1751/4885MAOB 934/4885ALDH1A1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.